First reported by Blockonomi
Q32 Bio (QTTB) Shares Soar 60% After Positive Alopecia Treatment Trial Results
Q32 Bio stock soared after its alopecia drug cleared a key clinical bar
The biotech's Phase 2a study of bempikibart showed a 35.3% mean reduction in hair loss scores, with the company planning a registration-directed program by early 2027
Read the full articleYou might also wanna read
Q32 Bio (QTTB) Shares Soar 60% After Positive Alopecia Treatment Trial Results
Q32 Bio (QTTB) stock soared 60% after bempikibart achieved primary endpoint in Phase 2a alopecia trial, showing 35.3% SALT score reduction w
Blockonomi·3d ago
STAT+: Roche ends Huntington’s gene-silencing programs
ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout
STAT·6d ago
FBRX Stock On Track For Biggest Single-Day Gains In 20 Months – What’s Behind The Super Rally?
Forte Biosciences announced results from its early-stage study for its investigational drug to treat an autoimmune skin condition.
Asianet Newsable·7d ago
Why Q32 Bio Stock Skyrocketed Today
The biotech is advancing a potential treatment for a common autoimmune disease.
Bars·2d ago
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
The company recently wowed investors with clinical trial results.
Bars·11d ago
Biogen (BIIB) Gains FDA Approval for Subcutaneous Alzheimer's Treatment Leqembi Iqlik
Related Stocks: BIIB
GuruFocus·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.